HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 06, June 2017 – Advocacies in Support of Rare Disease Patients       » Bayer and NUS Enterprise Announce Winners of Grants4Apps? Singapore Open Innovation Challenge       » Cancer Control Efforts in Vietnam: Interview with Dr Tran Thanh Huong       » China Sets up National Lab Developing Brain-Like AI Technology       » New Womb-Like Invention for Preterm Infants       » World Asthma Day: Managing and Living with Asthma       » Managing Liver Cancer as a Global Health Problem      
INSIDE INDUSTRY For e-subscribers (PDF)
Vol 21, No 04, April 2017
ATOZET® a New Combination Treatment Option for High-Risk Patients to Lower LDL Cholesterol, is Now Approved in Singapore

MSD (known as Merck in the US and Canada) announced on Feb 28 the approval of ATOZET (ezetimibe and atorvastatin) in Singapore by the Health Sciences Authority (HSA). The approval helps to address an urgent medical need as a recent Dyslipidemia International Study (DYSIS) revealed more than 70 per cent of patients from thirty countries worldwide (across Europe, the Middle East, Canada, Africa and...

ASEAN+ Rare Disease Network Established

SINGAPORE, 22 March 2017 — The first ASEAN+ Rare Disease Network has been established, bringing together patient support groups from across Southeast Asia (Singapore, Malaysia, Indonesia, the Philippines and Vietnam) and Hong Kong. The mission of this Network is to better understand the needs of rare disease patients and their caregivers in the region, in order to identify areas for improvement...

Luye Medical Joins Forces with OncoCare To Expand Its Integrated Healthcare Services Platform for Their Patients

Singapore-based Luye Medical Group has entered into a strategic partnership with OncoCare Cancer Centre furthering its ongoing strategy to make private healthcare services more integrated and available. OncoCare is the second largest private oncology treatment center in Singapore with strong growth in the last few years. With new equity investment from Luye Medical, the integrated oncology specialists...

NUS Pharmacy Team Develops Online "Calculator" to Predict Risk of Early Hospital Readmission

Patients who are discharged after a hospital stay will want to stay away from the hospital for as long as possible. However, in Singapore, approximately 15 per cent of patients who have been discharged from hospitals will succumb to a readmission within 30 days, while globally, readmission rates within 30 days can be as high as 20 per cent. The good news is, studies have shown that readmissions within 15 days...

The Bare Essentials: Ensuring Affordable Access to Insulin

The cost and availability of insulin is a growing concern and an issue of worldwide importance. The skyrocketing list prices of insulin-along with those of certain other drugs and medical products-in the USA became a major political issue last year. More recently, in January, 2017, a lawsuit was filed in a federal court in Massachusetts alleging that the three pharmaceutical companies that control the...

AstraZeneca's CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Death and Hospitalisations for Heart Failure Versus Other Type-2 Diabetes Medicines

AstraZeneca announced results of the first large real-world evidence study of its kind evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving treatment with a newer class of diabetes medicines, SGLT-2 inhibitors (SGLT-2i). [1] The CVD-REAL study assessed data from more than 300,000 patients across six countries, 87% of whom did not...

NEWS CRUNCH  
news The Seventh International Meeting on Synthetic Biology (SB 7.0)
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy